Matching trials
1,853 results
- Global Study to Evaluate the Long-Term Safety and Efficacy of Elagolix in Women With Moderate to Severe Endometriosis-associated Pain: Complete Statistical AnalysisIndependent statistical analysis of Global Study to Evaluate the Long-Term Safety and Efficacy of Elagolix in Women With Moderate to Severe Endometriosis-associated Pain: primary endpoint results, effect estimate with confidence interval, sample-size…
- GLOWIndependent statistical analysis of the phase 3 GLOW trial of zolbetuximab plus CAPOX versus placebo plus CAPOX in CLDN 18.2-positive, HER2-negative gastric or gastroesophageal junction adenocarcinoma, including time-to-event methodology, reported efficacy results,…
- Glycemic Efficacy and Renal Safety Study of Dapagliflozin in Subjects With Type 2 Diabetes Mellitus and Moderate Renal Impairment: Complete Statistical AnalysisIndependent statistical analysis of Glycemic Efficacy and Renal Safety Study of Dapagliflozin in Subjects With Type 2 Diabetes Mellitus and Moderate Renal Impairment: primary endpoint results, effect estimate with confidence interval, sample-size…
- GO-VIVAIndependent statistical analysis of A Study to Evaluate the Pharmacokinetics, Efficacy and Safety of Intravenous Golimumab in Pediatric Participants With Active Polyarticular Course Juvenile Idiopathic Arthritis Despite Methotrexate Therapy: primary endpoint results,…
- Golimumab in Rheumatoid Arthritis Participants With an Inadequate Response to Etanercept (ENBREL) or Adalimumab (HUMIRA): Complete Statistical AnalysisIndependent statistical analysis of Golimumab in Rheumatoid Arthritis Participants With an Inadequate Response to Etanercept (ENBREL) or Adalimumab (HUMIRA): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety,…
- GOLMePsAIndependent statistical analysis of GOLimumab and Methotrexate Versus Methotrexate in Very Early PsA: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT04108468).
- GRACE: A Study to Compare the Effectiveness, Safety and Tolerability of PREZISTA (Darunavir)/Ritonavir by Gender and Race When Administered With Other Antiretroviral Medications in Human Immunodeficiency Virus (HIV) Positive Women and Men.: Complete Statistical AnalysisIndependent statistical analysis of GRACE: A Study to Compare the Effectiveness, Safety and Tolerability of PREZISTA (Darunavir)/Ritonavir by Gender and Race When Administered With Other Antiretroviral Medications in Human Immunodeficiency Virus (HIV)…
- GRAMSIndependent statistical analysis of Gadobutrol Enhanced MRA of the Renal Arteries: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01344460).
- GRAVITYIndependent statistical analysis of 12-week Open-label, Phase IIIb Comparing Efficacy and Safety of Rosuvastatin (CRESTOR™) in Combination With Ezetimibe: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety,…
- Grazoprevir (MK-5172) and Elbasvir (MK-8742) Combination for Chronic Hepatitis C Virus (HCV) Genotypes 1, 4, and 6 (MK-5172-065): Complete Statistical AnalysisIndependent statistical analysis of Grazoprevir (MK-5172) and Elbasvir (MK-8742) Combination for Chronic Hepatitis C Virus (HCV) Genotypes 1, 4, and 6 (MK-5172-065): primary endpoint results, effect estimate with confidence interval, sample-size planning…
- GRECCAR 2Independent statistical analysis of GRECCAR 2, a randomized phase 3 trial comparing local rectal excision with total mesorectal excision in rectal neoplasms, including its composite 24-month primary endpoint and planned statistical interpretation.
- GRIPHONIndependent statistical analysis of the GRIPHON phase 3 trial of selexipag in pulmonary arterial hypertension, covering its randomized time-to-event endpoint, secondary analyses, statistical methods, confidence intervals, and interpretation.
- GS-US-292-0104Independent statistical analysis of GS-US-292-0104 (NCT01780506), a randomized phase 3 trial comparing E/C/F/TAF with E/C/F/TDF in antiretroviral treatment-naive adults with HIV-1 infection, including its non-inferiority analysis, risk difference, confidence interval, and Cochran-Mantel-Haenszel…
- GSK1120212 vs Chemotherapy in Advanced or Metastatic BRAF V600E/K Mutation-positive Melanoma: Complete Statistical AnalysisIndependent statistical analysis of GSK1120212 vs Chemotherapy in Advanced or Metastatic BRAF V600E/K Mutation-positive Melanoma: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…
- GSK1550188 A 52 Week Study of Belimumab Versus Placebo in the Treatment of Subjects With Systemic Lupus Erythematosus (SLE) Located in Northeast Asia: Complete Statistical AnalysisIndependent statistical analysis of GSK1550188 A 52 Week Study of Belimumab Versus Placebo in the Treatment of Subjects With Systemic Lupus Erythematosus (SLE) Located in Northeast Asia: primary endpoint results, effect estimate…
- GWPCARE5Independent statistical analysis of An Open Label Extension Study of Cannabidiol (GWP42003-P) in Children and Adults With Dravet or Lennox-Gastaut Syndromes: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration,…
- HALT PKD AIndependent statistical analysis of HALT Progression of Polycystic Kidney Disease Study A: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00283686).
- HARMONIZE GLIndependent statistical analysis of A Study to Investigate the Safety and Efficacy of ZS in Patients With Hyperkalemia: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…
- HEAL-COVIDIndependent statistical analysis of HEAL-COVID (NCT04801940), a randomized phase 3 trial evaluating apixaban and atorvastatin in patients with Covid19.
- HEART-FIDIndependent statistical analysis of Randomized Placebo-controlled Trial of FCM as Treatment for Heart Failure With Iron Deficiency / and Sub-Study: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and…
- Heme Iron Polypeptide for Iron Deficiency Anemia in Chronic Renal Failure: Complete Statistical AnalysisIndependent statistical analysis of Heme Iron Polypeptide for Iron Deficiency Anemia in Chronic Renal Failure: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…
- Hemophilia Adult Prophylaxis Study: Factor VIII in Severe Hemophilia A: Complete Statistical AnalysisIndependent statistical analysis of Hemophilia Adult Prophylaxis Study: Factor VIII in Severe Hemophilia A: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01405742).
- HEROIndependent statistical analysis of A Study to Evaluate the Safety and Efficacy of Relugolix in Men With Advanced Prostate Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and…
- HEXT (Hypo EXTended): Effect of PTH on Skeleton in Hypoparathyroidism: Complete Statistical AnalysisIndependent statistical analysis of HEXT (Hypo EXTended): Effect of PTH on Skeleton in Hypoparathyroidism: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01199614).
- High Dose Esomeprazole Na for Prevention of Rebleeding After Successful Endoscopic Therapy of a Bleeding Peptic Ulcer: Complete Statistical AnalysisIndependent statistical analysis of High Dose Esomeprazole Na for Prevention of Rebleeding After Successful Endoscopic Therapy of a Bleeding Peptic Ulcer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration,…
- High Dose Oxytocin Nasal Spray for Treatment of Tinnitus: Complete Statistical AnalysisIndependent statistical analysis of High Dose Oxytocin Nasal Spray for Treatment of Tinnitus: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT04210310).
- HIMALAYAComplete statistical analysis of the phase 3 HIMALAYA trial of durvalumab and tremelimumab in advanced hepatocellular carcinoma, including trial design, overall survival, non-inferiority methodology, Cox regression, log-rank testing, and interpretation.
- HIV Vaccine Trial in Thai Adults: Complete Statistical AnalysisIndependent statistical analysis of HIV Vaccine Trial in Thai Adults: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00223080).
- Hokusai Study in Pediatric Patients With Confirmed Venous Thromboembolism (VTE): Complete Statistical AnalysisIndependent statistical analysis of Hokusai Study in Pediatric Patients With Confirmed Venous Thromboembolism (VTE): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02798471).
- Home-HF: Evaluation of Patients With Heart Failure Using Home Telemonitoring: Complete Statistical AnalysisIndependent statistical analysis of Home-HF: Evaluation of Patients With Heart Failure Using Home Telemonitoring: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00312884).
- HORIZON IIIndependent statistical analysis of Cediranib (AZD2171, RECENTIN™) in Addition to Chemotherapy in Patients With Untreated Metastatic Colorectal Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…
- HORIZON-HCMIndependent statistical analysis of A Study of Mavacamten in Obstructive Hypertrophic Cardiomyopathy: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT05414175).
- Hormone Suppression and Radiation Therapy for 6 Months With/Without Docetaxel for High Risk Prostate Cancer: Complete Statistical AnalysisIndependent statistical analysis of Hormone Suppression and Radiation Therapy for 6 Months With/Without Docetaxel for High Risk Prostate Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety,…
- HSDDIndependent statistical analysis of 2. Study to Evaluate the Efficacy/Safety of Bremelanotide in Premenopausal Women With Hypoactive Sexual Desire Disorder: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and…
- HVTN 702Independent statistical analysis of HVTN 702, a randomized phase 2/3 HIV vaccine prevention trial evaluating ALVAC-HIV and bivalent subtype C gp120/MF59 versus placebo, including time-to-event methods, hazard ratios, confidence intervals, safety, and…
- Hydrochlorothiazide as add-on to Olmesartan/Amlodipine in Hypertension: Complete Statistical AnalysisIndependent statistical analysis of Hydrochlorothiazide as add-on to Olmesartan/Amlodipine in Hypertension: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00902538).
- Hydrocortisone for BPD: Complete Statistical AnalysisIndependent statistical analysis of Hydrocortisone for BPD: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01353313).
- Hydroxychloroquine as Post-Exposure Prophylaxis Against COVID-19 Infection: Complete Statistical AnalysisIndependent statistical analysis of Hydroxychloroquine as Post-Exposure Prophylaxis Against COVID-19 Infection: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT04372017).
- Hydroxychloroquine for the First Thrombosis Prevention in Antiphospholipid Antibody Positive Patients: Complete Statistical AnalysisIndependent statistical analysis of Hydroxychloroquine for the First Thrombosis Prevention in Antiphospholipid Antibody Positive Patients: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…
- Hypertonic Resuscitation Following Traumatic Injury: Complete Statistical AnalysisIndependent statistical analysis of Hypertonic Resuscitation Following Traumatic Injury: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00316017).
- IALTAn independent statistical analysis of IALT (NCT00002823), a randomized phase 3 trial comparing combination chemotherapy with no treatment following surgery in patients with lung cancer.
- Ibrexafungerp for the Treatment of Complicated Vulvovaginal Candidiasis: Complete Statistical AnalysisIndependent statistical analysis of Ibrexafungerp for the Treatment of Complicated Vulvovaginal Candidiasis: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT05399641).
- Ibuprofen Extended-Release Dental Pain Study: Complete Statistical AnalysisIndependent statistical analysis of Ibuprofen Extended-Release Dental Pain Study: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00707057).
- Ibuprofen With or Without Acetaminophen for Low Back Pain: Complete Statistical AnalysisIndependent statistical analysis of Ibuprofen With or Without Acetaminophen for Low Back Pain: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT03554018).
- ICEIndependent statistical analysis of Immune Globulin Intravenous (IGIV) For Chronic Inflammatory Demyelinating Polyneuropathy (CIDP): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00220740).
- ICON6A detailed statistical analysis of the ICON6 phase 3 randomized trial of concurrent and maintenance cediranib in women with platinum-sensitive relapsed ovarian cancer, including its design, progression-free survival endpoint, planned statistical analysis,…
- ICON7Independent statistical analysis of ICON7 (NCT00483782), a randomized phase 3 trial evaluating carboplatin and paclitaxel with or without bevacizumab in newly diagnosed ovarian epithelial, fallopian tube, or primary peritoneal cavity cancer.
- ICONIC-TOTALIndependent statistical analysis of A Study of JNJ-77242113 for the Treatment of Participants With Plaque Psoriasis Involving Special Areas (Scalp, Genital, and/or Palms of the Hands and the Soles of the Feet):…
- IDEAL-ICUIndependent statistical analysis of IDEAL-ICU, a randomized phase 3 trial evaluating early versus delayed initiation of renal replacement therapy in ICU patients with septic shock and acute renal failure.
- IDENTITY-2Independent statistical analysis of Effects of LY450139, on the Progression of Alzheimer's Disease as Compared With Placebo: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…